Table 2.

Age and race adjusted standardized incidence ratios (SIRs) for selected cancers among a cohort of patients with systemic lupus erythematosus (SLE), California, 1991–2002 (n = 30,478)^a

Cancer type	Observed	Expected	SIR	95% CI
All cancers	1,273	1,120.8	1.14	1.07–1.20
Breast	237	311.9	0.76	0.67–0.86
Ovary	27	32.8	0.82	0.54–1.20
Uterus	29	48.1	0.60	0.40–0.87
Vagina/vulva	49	15.0	3.27	2.41–4.31
Cervix	38	69.7	0.55	0.39–0.75
Prostate	43	62.2	0.69	0.50–0.93
Lung	218	131.2	1.66	1.45–1.90
Esophagus	12	6.5	1.85	0.95–3.22
Stomach	18	14.6	1.23	0.73–1.95
Colon/rectum	99	108.2	0.91	0.74–1.11
Liver	17	6.4	2.70	1.54–4.24
Pancreas	25	22.1	1.13	0.73–1.67
Bladder	31	28.0	1.11	0.75–1.57
Kidney	38	17.7	2.15	1.52–2.94
Thyroid	30	16.4	1.83	1.24–2.62
Br.1in/CNS	18	11.2	1.61	0.95–2.54
Non-Hodgkin’s lymphoma	96	35.1	2.74	2.22–3.34
Large B-cell	42	12.9	3.26	2.33–4.39
Follicular	26	9.0	2.89	1.88–4.22
Hodgkin’s disease	13	4.3	3.02	1.60–5.13
Leukemia	43	20.2	2.13	1.49–2.77
Lymphoid	9	8.7	1.03	0.47–1.96
Myeloid	29	9.8	2.96	1.99–4.26
Monocytic	2	0.4	5.00	0.68–20.17
Myeloma	15	11.1	1.35	0.76–2.23
Melanoma	37	54.9	0.67	0.47–0.93

^aSIR = standardized incidence ratio; CI = confidence interval